Evidence map›Paper›PMID 41877227›Full record

ArticleBMC medicine2026

Digenic inheritance of mutations in SPG7 and AFG3L2 causes motor neuron and cerebellar disorders.

Mehrdad A Estiar, Eric Yu, Parizad Varghaei, Jay P Ross, Setareh Ashtiani, Andrew N Bayne, Giulia Coarelli, Dagmar Timmann, Thomas Klockgether, Danique Beijer and 17 more

Abstract read
In one paragraph

Article in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Mehrdad A EstiarDepartment of Human Genetics, McGill University, Montréal, Québec, Canada.
Eric YuDepartment of Human Genetics, McGill University, Montréal, Québec, Canada.
Parizad VarghaeiDepartment of Psychiatry, University of Ottawa, Ottawa, ON, Canada.
Jay P RossDepartment of Human Genetics, McGill University, Montréal, Québec, Canada.
Setareh AshtianiAlberta Children's Hospital, Medical Genetics, Calgary, Canada.
Andrew N BayneDepartment of Pharmacology and Therapeutics, McGill University, Montréal, Québec, Canada.
Giulia CoarelliSorbonne Université, Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, and Reference Center for Rare Diseases «Neurogenetics», Department of Medical Genetic, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.
Dagmar TimmannDepartment of Neurology and Center for Translational Neuro- and Behavioral Sciences, University Hospital Essen, University of Duisburg-Essen, Duisburg, Germany.
Thomas KlockgetherGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Danique BeijerDivision of Translational Genomics of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany.
David MengelDivision of Translational Genomics of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany.
Marie CoutelierSorbonne Université, Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, and Reference Center for Rare Diseases «Neurogenetics», Department of Medical Genetic, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.
Project MinE ALS Sequencing Consortium
Patrick A DionDepartment of Human Genetics, McGill University, Montréal, Québec, Canada.
Oksana SuchowerskyDepartments of Medicine (Neurology) and Medical Genetics, University of Alberta, Edmonton, Canada.
Claire EwenczykSorbonne Université, Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, and Reference Center for Rare Diseases «Neurogenetics», Department of Medical Genetic, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.
Cyril GoizetReference Center for Rare Diseases «Neurogenetics», Department of Medical Genetic, UMR 5287, Bordeaux University Hospital, and Univ. Bordeaux, CNRS, INCIA, NRGenTeam, Bordeaux, France.
Giovanni StevaninReference Center for Rare Diseases «Neurogenetics», Department of Medical Genetic, UMR 5287, Bordeaux University Hospital, and Univ. Bordeaux, CNRS, INCIA, NRGenTeam, Bordeaux, France.
Philip Van DammeDepartment of Neurology, Neuromuscular Reference Center, University Hospitals Leuven, Louvain, Belgium.
Ammar Al-ChalabiDepartment of Clinical Neuroscience, King's College London, London, UK.
Stephan ZuchnerDr. John T. Macdonald Foundation, Department of Human Genetics and John P, Hussman Institute for Human Genomics, University of Miami, Miller School of Medicine, Miami, FL, USA.
Matthis SynofzikDivision of Translational Genomics of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany.
Jan H VeldinkDepartment of Neurology, University Medical Center Utrecht, Utrecht, The Netherlands.
Jean-Francois TrempeDepartment of Pharmacology and Therapeutics, McGill University, Montréal, Québec, Canada.
Alexandra DurrSorbonne Université, Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, and Reference Center for Rare Diseases «Neurogenetics», Department of Medical Genetic, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.
Guy A RouleauDepartment of Human Genetics, McGill University, Montréal, Québec, Canada.
Ziv Gan-OrDepartment of Human Genetics, McGill University, Montréal, Québec, Canada. ziv.gan-or@mcgill.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBiallelic SPG7 mutations cause one of the most common forms of hereditary spastic paraplegia (HSP). Several reports have suggested that heterozygous SPG7 variants may also play a role in HSP, but also in amyotrophic lateral sclerosis (ALS). However, it remains controversial whether heterozygous SPG7 mutations are pathogenic on their own, or if other mechanisms are at play. We recently provided evidence for non-Mendelian inheritance in spastic paraplegia 7 (SPG7), as heterozygous carriers of SPG7 mutations often also carried mutations in other disease-related genes, including AFG3L2, more frequently than expected by chance. Given that SPG7 and AFG3L2 encode interacting subunits of the mitochondrial m-AAA protease complex, we hypothesized that combined heterozygous mutations in these genes may act synergistically to disrupt mitochondrial function and contribute to disease. In this study, we aimed to examine whether digenic heterozygous mutations in SPG7 and AFG3L2 can lead to a spectrum of neurodegenerative disorders.

methodsWe first analyzed genome and exome sequencing data of 6644 unrelated individuals including 4817 motor neuron disorder (MND) and ataxia patients and 1827 controls. We next analyzed an additional 18,748 exome data from rare disease cohorts to further examine the occurrence of variants in SPG7 and AFG3L2.

resultsAmong the first 4817 MND and ataxia patients, we identified a total of 6 patients, 4 of whom were unrelated, who carried potentially pathogenic variants in both SPG7 and AFG3L2, in contrast to none in 1827 unrelated controls. Further analysis of the 18,748 additional patients with rare disease, as well as a comprehensive literature review, identified 6 more patients, 5 of whom were unrelated, who had digenic mutations in SPG7 and AFG3L2. In the two families we identified, digenic mutations in SPG7 and AFG3L2 perfectly segregated with the disease. The 12 patients reported here exhibited predominant signs of motor neuron and cerebellar involvement.

conclusionsOur findings demonstrate that digenic inheritance of concurrent heterozygous mutations in SPG7 and AFG3L2 may cause motor neuron and cerebellar disorders. Screening of the entire SPG7 and AFG3L2 genes in genetically undiagnosed cases of MND and spastic ataxia may help to increase the diagnostic yield.

Indexed as

ATPases Associated with Diverse Cellular ActivitiesATP-Dependent ProteasesCerebellar DiseasesMetalloendopeptidasesMotor Neuron DiseaseMutationSpastic Paraplegia, HereditaryFemaleHeterozygoteHumansMaleAFG3L2 protein, humanATPases Associated with Diverse Cellular ActivitiesATP-Dependent ProteasesMetalloendopeptidasesSPG7 protein, humanAFG3L2AtaxiaCerebellar disorderLateral sclerosisMotor neuron disorderSPG7

Identifiers

PMID41877227
PMCPMC13134353

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.